AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03032796 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Body Trainer
Description: A novel video game-based intervention that incorporates physiological measures such as heart rate into the core game mechanics, with motion capture technology to incorporate whole-body kinematics into game play. This group will train for 36 minutes per day, 3 days a week for 8 weeks. The Body Trainer group will train using closed-loop adaptive algorithms to challenge physical performance as guided by heart rate, such that the amount of movement needed to respond on each task will dynamically change depending upon the participant being below/above a predetermined derived level of exertion. During Body Training, participants will only perform a basic reaction task in each level/module to ensure only the most minimal cognitive challenge is present
Study NCT03032796 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain Trainer
Description: The Brain Trainer group will train using the aforementioned closed-loop adaptive algorithms to challenge cognitive performance, except while sitting down and playing with an Xbox control pad (thus removing all physical training aspects). This group will train for 36 minutes per day, 3 days a week for 8 weeks.
Study NCT03032796 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Expectancy Matched Control
Description: The placebo-matched control group will engage in a battery of three apps (playing each app 10 minutes per day, 5 days a week for 8 weeks completed in the laboratory that we believe will have no significant impact on the cognitive or physical fitness measures we are assessing: i) an app with 100 different logic games of varying difficulty and length, ii) a language-learning app with 10 language options, and iii) an app that offers a guided Tai Chi program. We have pre-determined that this approach generates matched expectancy compared to our training groups: we asked 100 naïve individuals to predict how they would expect to improve performance on our outcome measures after training on one of these platforms, revealing that placebo training generates equivalent expectations of improvement across each outcome measure as the BBT group.
Study NCT00514332 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stent
Description: stent placement for colorectal cancer obstruction
Study NCT01700790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir and ritonavir
Description: Two tablets twice daily of Lopinavir/ritonavir 200 mg/50mg with 3 capsules of ritonavir 100 mg twice daily given with rifampin 600 mg daily
Study NCT01724788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FUROSEMIDE
Description: Pharmaceutical form: Solution Route of administration: Intravenous
Study NCT01724788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FUROSEMIDE (HOE058)
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study NCT00320489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: 10 milligrams (mg), oral tablets, once daily for 4 weeks followed by 5-20 mg flexible dosing, oral tablets, once daily, for 100 weeks, for a total treatment duration of 104 weeks.
Study NCT00320489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine pamoate depot
Description: 405 milligrams (mg), intramuscular injection, followed 4 weeks later by 150-405 mg flexible dosing, intramuscular injection, every 4 weeks thereafter for 96 weeks, for a total treatment duration of 104 weeks.
Study NCT00697229 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix™-B
Description: Intramuscular injection, 1 or 3 doses
Study NCT00697229 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine
Description: Intramuscular injection, 1 or 3 doses
Study NCT05586750 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x 20mg placebo (daily), taken orally. Identical appearance to study drug
Study NCT03805399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PARP inhibitor included therapy
Description: If patients were BLIS subtype and had a BRCA gene pathogenic mutation, she will receive PARP inhibitor SHR3162 150mg bid and famitinib 20mg qd continuously .
Study NCT03805399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLIS with anti-VEGFR included therapy
Description: If patients were BLIS subtype and did not have a BRCA gene pathogenic mutation , she will receive:~E2: apatinib 250mg qd continuously combined with VP-16 50mg qd (three week on one week off); E3: famitinib 20mg qd continuously combined with VP-16 50mg qd (three week on one week off); E4: BP102 10mg/kg d1,d15 combined with nab-paclitaxel 100mg d1,d8,d,15; q4w
Study NCT03805399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MES with anti-VEGFR included therapy
Description: If patients were MES subtype and without PI3K/AKT pathway activation,she will receive famitinib 20mg qd continuously combined with VP-16 50mg qd (three week on one week off).
Study NCT03741270 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabivax-S
Description: Rabivax-S is a lyophilized vaccine manufactured by Serum Institute of India Pvt. Ltd. containing inactivated purified rabies antigen (Pitman Moore, PM3218 as virus strain) produced using Vero ATCC CCL 81 cells. The diluent (sterile water for injection) is provided in a separate 1 mL ampoule. After reconstitution, a single dose of 1 mL contains an inactivated, purified rabies antigen (not less than 2.5 IU), glycine (40 mg), sucrose (40 mg) and human serum albumin (25% 10 mg). The intervention is administered by intramuscular injection of 1 mL reconstituted vaccine in the deltoid area of the upper arm, on days 0, 7 and 21 (or 28).
Study NCT03805399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mTOR inhibitor with nab-paclitaxel
Description: If patients were MES subtype and had PI3K/AKT pathway activation, she will receive mTOR inhibitor 10mg qd continuously combined with nab-paclitaxel 100mg qw (three week on one week off).
Study NCT00450255 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ziv-aflibercept
Description: Given IV
Study NCT00398710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: 150 mg daily (100 mg daily in case of dose reduction)
Study NCT04044391 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CardioFlux Magnetocardiograph
Description: CardioFlux is a noninvasive diagnostic modality which can measure and image the heart's intrinsic magnetic field created by ion transit across cardiac cell membranes.
Study NCT02843633 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioFreedom™ Drug Coated Coronary Stent System
Description: a non-surgical procedure that uses a catheter to place a stent to open up coronary arteries that have been narrowed by atherosclerosis
Study NCT02843633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiplatelet Drug
Description: Dual antiplatelet therapy for one month followed by single antiplatelet therapy indefinitely. Aspirin and clopidogrel (or other P2Y12 inhibitor) will be used and dosing is according to standard institutional practice
Study NCT00450255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02552875 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tetanic stimulation
Description: 50 Hz tetanic stimulation before TOF-twitch stabilization with the aim to eliminate the staircase phenomenon
Study NCT02552875 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Staircase Stimulation
Description: TOF-twitch stabilization without 50 Hz tetanic stimulation with the aim to verify the staircase phenomenon
Study NCT04017858 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiprofessional and educational Program prior to Total knee replacement TKA. (PARQVE TKA).
Description: Patients will participate in two days of about knee OA lectures two months apart, will also come to the hospital at months 1, 3 and 5 after the first class to consult about nutritional habits; at months 4 and 6 to participate in a group therapy session with the psychologists, 7 sessions with the physical therapy followed by 7 sessions with the physical educators team. Following this program, patients will be operated (total knee arthroplasty).~Answer Womac, VAS, Lequesne, BMI and body fat percentage - at inclusion, one week prior to surgery, 1 and 6 months postoperatively.~Days of hospital stay will be measured by the number of nights the patients stay in the hospital postoperatively and also days in semi-intensive.~Minutes and type of physical activity - Answer at inclusion and six months postoperatively.~Perform STS30 and TUG at inclusion, one week prior to surgery, 1 and 6 months postoperatively Costs will be evaluated for cost-effectiveness and cost-utility analysis
Study NCT04017858 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patients will be submitted to total knee replacement.
Description: Patients will be submitted to total knee replacement, without Multiprofessional and educational Program Answer Womac, VAS, Lequesne, BMI and body fat percentage - at inclusion, one week prior to surgery, 1 and 6 months postoperatively.~Days of hospital stay will be measured by the number of nights the patients stay in the hospital postoperatively and also days in semi-intensive.~Minutes and type of physical activity - Answer at inclusion and six months postoperatively.~Perform the STS30 and TUG at inclusion, one week prior to surgery, 1 and 6 months postoperatively
Study NCT02609594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weekly application of Amnioband
Description: Weekly application of Amnioband.
Study NCT02609594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biweekly application of Amnioband
Description: Biweekly application (every two weeks) of Amnioband.
Study NCT02609594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care for this study is weekly multi-layer compression bandaging.
Study NCT02609594 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care for this study is weekly multi-layer compression bandaging.
Study NCT00137605 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax
Study NCT00137605 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar
Study NCT02659241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Given PO
Study NCT02659241 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03979001 — intervention group
Intervention type: OTHER
Intervention: complete ophthalmological examination
Description: collection:~* ophthalmological history and current treatments~* occular tension measurement~* measurement of visual acuity (Snellen chart)~* Axial length measurement~* Photograph of the posterior segment of the eye~* 3x3 and 6x6 macular and papillary OCT angiography
Study NCT04354857 — intervention group
Intervention type: OTHER
Intervention: olfactory and gustatory tests
Description: Participants rate quality of sense of smell and taste.~Olfaction test: Sniff 10ml test tube containing 1.5ml air freshner (Mifleur Citron, Coldis, Entraigues sur Sorgues, France) and rate perception of odor.~Gustatory test: Taste a pinch and sugar and salt and rate perception of sweet or salty taste
Study NCT00867152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Darunavir 600 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Darunavir is approved by the FDA as an HIV medication in the protease inhibitor class.
Study NCT00867152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine
Description: Etravirine 200 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Etravirine is approved by the FDA as an HIV medication in the non-nucleoside reuptake inhibitor class.
Study NCT00867152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir 100 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class.
Study NCT00867152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: Lopinavir 400 mg and ritonavir 100 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Lopinavir/Ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class.
Study NCT00867152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: GSK1349572 50 q24h for 5 days in Period 1 and for 14 days in Period 2. GSK1349572 20 mg q12h for 14 days in Period 3 if Period 3 is done. GSK1349572 is an investigational (not approved by the FDA) HIV medication in the integrase inhibitor class.
Study NCT03888027 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WalkMORE group
Description: Hospitalized Internal Medicine patients will walk with trained volunteers twice daily until hospital discharge.
Study NCT04219020 — intervention group
Intervention type: OTHER
Intervention: Co-created intervention
Study NCT03110562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: oral 100 mg dose
Study NCT03110562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: subcutaneous dose of 1.3 mg/m2
Study NCT03110562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: oral dose of 20mg
Study NCT02722356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin administered per oxytocin group or standard practice group (see above)
Study NCT02722356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin administered per oxytocin group or standard practice group (see above)
Study NCT04138433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real tDCS
Description: Anodal tDCS 2 ma
Study NCT04138433 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham tDCS 2 ma
Study NCT02322216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine Hydrochloride Ophthalmic Solution 0.2%
Study NCT02322216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine Hydrochloride Ophthalmic Solution 0.1%
Study NCT02322216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.2% Vehicle
Description: Inactive ingredients used as placebo comparator
Study NCT04443452 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative Sensory Testing
Description: PPT: An electronic data collection unit will be used featuring an electronic algometer connected with a laptop where the amount of pressure will be displayed on the screen. When the pressure pain detection threshold is reached (the point where the pressure sensation starts to be experienced as pain), the individual will press a button at a handheld device, that will automatically store the pressure value in the system and serve as an indication, for the examiner, to stop the testing.~TS: A pinprick stimulator (Weight: 256mNewton) will be used. The examiner will apply the pen that features a retractable blunt needle in a repetitive manner (once per second for ten seconds). The individual will be asked for the intensity of pain (NRS) at the first and at the last time and the given score will be noted.~CPM: A manual blood pressure sphygmomanometer will be used in conjunction with the electronic algometer described above (PPT).
Study NCT04443452 — intervention group
Intervention type: RADIATION
Intervention: Radiographic Evaluation
Description: Tibiofemoral and patellofemoral radiographs of the most painful knee will be taken using a standardised protocol (standing posterior-anterior (PA) and skyline views) and will be scored by a single experienced observer in order to generate data for correlation analyses with the primary and secondary outcomes. A Perspex Rosenberg template with lead beads is used for the standing PA view to standardising the degree of knee flexion, foot rotation and magnification. PA radiographs are taken with the participant facing the x-ray tube while standing on the Rosenberg jig and leaning forwards with their thighs touching the anterior aspect of the jig, the x-ray beams passing from the posterior aspect through to the anterior aspect of the knee. Variable jigs are used for the skyline view to obtaining 300 of knee flexion with the participant lying in a reclined supine position on a couch. Grading of radiographs for changes of OA will be based on the Kellgren and Lawrence (K/L) score.
Study NCT04443452 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasound-guided Aspiration
Description: Ultrasound scanning will be conducted on the most painful knee to identify synovial effusion. During the ultrasound scan, the supra-patellar pouch, medial and lateral recess of the knees will be assessed for synovial thickening, synovial fluid/effusion and for positive power Doppler. An ultrasonic probe will be used to direct ultrasonic waves onto the knee joint during sonography, and a computer converts the signals received so that they can be presented on the screen. During skin application, a sterile probe cover and sterile acoustic gel will be used. Once the best aspiration location is identified and the location of the needle insertion marked, the skin will be prepared with a cleansing agent such as iodine or chlorhexidine. The needle may be introduced into the skin either parallel to the probe or perpendicular to the probe. Once the aspiration is completed, the needle will be removed, the skin cleansed, and a bandage will be applied.
Study NCT04443452 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle Strength Assessment
Description: Isometric testing will be done at 30 and 60 degrees of flexion as done in the previous study and the participant will be in sitting position with hips and knees strapped to keep the position standardised.
Study NCT02659683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium 40 mg DR Capsules of AstraZeneca LP, USA
Description: oral, cross over
Study NCT02659683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torrent's Esomeprazole Magnesium DR Capsules 40 mg
Description: oral, cross over
Study NCT04301882 — intervention group
Intervention type: DRUG
Intervention: interferon combined with ribavirin (PR) antiviral therapy
Description: Patients with chronic hepatitis C treated with interferon combined with ribavirin (PR) antiviral therapy (PR therapy greater than or equal to 6 months)
Study NCT04301882 — intervention group
Intervention type: DRUG
Intervention: direct antiviral drugs (DAAs)
Description: Patients with chronic hepatitis C treated with direct antiviral drugs (DAAs)
Study NCT03126929 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coma Recovery Scale-Revised and Glasgow Coma Scale
Description: Patients have been assessed with both the Coma Recovery Scale-Revised(CRS-R) and the Glasgow Coma Scale(GCS)
Study NCT04439630 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nopal fractions
Description: Nopal flour were divided in two fractions and mixed in two different test breads
Study NCT04439630 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Test product without the active components
Description: Test product without the active components
Study NCT01253681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386, paclitaxel and carboplatin
Description: 15 mg/Kg AMG 386 IV (intravenous) weekly plus paclitaxel and carboplatin IV Q3W for 18 weeks, followed by 15mg/Kg AMG 386 IV (intravenous) weekly alone for an additional 18 months.
Study NCT03384290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRS-060
Description: Drug
Study NCT04307472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Nudge
Description: Text message sent to patients to prompt awareness of statin eligibility before an appointment with their primary care physician
Study NCT02865941 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortification with modular protein
Description: Modular product supplementation is based on most recent breast analysis done for the participant.
Study NCT02865941 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortification with modular carbohydrate
Description: Modular product supplementation is based on most recent breast analysis done for the participant.
Study NCT02865941 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortification with modular fat
Description: Modular product supplementation is based on most recent breast analysis done for the participant.
Study NCT02676245 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Viewing Newborn Screening movie
Description: NBS Movie and printed brochure were viewed by the participants
Study NCT02676245 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Viewing Residual Dried Blood Spot movie
Description: DBS Movie and and printed brochure were viewed by the participants
Study NCT04443452 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Function Assessment (A)
Description: The participant will start in a seated position. The participant will stand up upon therapist's command, walk 3 meters, turn around, walk back to the chair and sit down. The time will stop when the participant is seated. The subject can use an assistive device. If the assistive device is used, it will be documented.~Important Note: A practice trial will be completed before the timed trial.
Study NCT03384290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PRS-060 Matching Placebo
Study NCT02274675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy for wrist and forearm
Description: Robot therapy by using a single degree reconfigurable robot to train for wrist and forearm rehabilitation training.